InvestLog
ERNA Ernexa Therapeutics Inc. logo

ERNA Ernexa Therapeutics Inc.

Healthcare
$11.99-3.77%ClosedMarket Cap: $3.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.38

P/S

0.00

EV/EBITDA

0.36

DCF Value

$1.88

FCF Yield

-192.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-263.7%

ROA

-108.0%

ROIC

-138.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-5.5M$—
Q4 null$0.00$-1.5M$—
FY null$0.00$-14.1M$—
Q3 null$0.00$-1.2M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Cherington Charles10 percent owner
BuyTue Feb 17
Gurrola Sandra Mofficer: Sr. VP of Finance
SellMon Jul 07
Cherington Charles10 percent owner
BuyWed Jun 11
Cherington Charles10 percent owner
BuyWed May 07
Cherington Charles10 percent owner
BuyWed May 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

1.89

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Peers

ADAP logoADAPAEMD logoAEMDAEON logoAEONDWTX logoDWTXLNAI logoLNAIMBRX logoMBRXMPLT logoMPLTOSRH logoOSRHPHGE logoPHGEPMN logoPMN